Terrance P. Coyne

CFO Terrance P. Coyne sold entire 64.4K share position in RPRX for $3.5M under pre-arranged 10b5-1 plan

Terrance P. Coyne, EVP & CFO, sold 64,399 shares of Royalty Pharma plc at $53.98 on 2026-05-26, liquidating his complete shareholding. This transaction was executed pursuant to a pre-arranged 10b5-1 trading plan adopted on 2026-02-24, meaning the sale was scheduled rather than discretionary. At the time of sale, RPRX traded at $53.98 against a current price of $54.48 and a 52-week high of $54.74, placing the transaction near the high end of the range. Coyne's prior trades at RPRX show mixed post-sale price performance: five preceding sales at this ticker yielded 30-day returns ranging from +2.4% to +9.2% and 90-day returns from +8.4% to +18.5%, while his broader cross-ticker track record across 20 prior sells averaged +7.0% 30-day and +16.6% 90-day returns. The company's fundamentals remain solid with $630.6M quarterly revenue, $294.7M net income, and +5.1% annual revenue growth, though the P/E of 25.58 reflects a mature valuation. The complete exit by a top finance executive warrants attention given his prior history at this ticker, though the scheduled nature of the trade precludes timing-based inference.

CFO Terrance Coyne sells nearly all RPRX shares in dual-tranche sale worth $1.73M near 52-week highs.

Coyne Terrance P., the company's Chief Financial Officer, liquidated his entire equity stake in Royalty Pharma across two transactions, divesting over $1.7 million in total value. The timing is noteworthy: the stock has rallied significantly in recent months and is currently trading near its 52-week highs, which is the opposite pattern from typical insider confidence-driven sales that usually occur during weakness or consolidation. Royalty Pharma is a profitable, revenue-growing business with solid fundamentals, so the sale doesn't signal financial distress at the company level. However, a CFO liquidating 100% of personal holdings at elevated valuations—rather than trimming positions gradually or during dips—suggests either portfolio rebalancing, estate planning, or a preference to reduce exposure at favorable pricing. This complete exit warrants monitoring to see whether other insiders follow suit or if the CFO's sales represent an isolated tax or personal liquidity event.

CFO Coyne sells 34,791 shares (34.8K) at $48.33 for $1.7M, reducing RPRX stake by -51.4%

CFO Terrance P. Coyne executed 2 separate sales totaling 34,791 shares for $1,681,511.66 at $48.33 on April 1, 2026, reducing his holdings from 67,707 to 32,916 shares. This represents a -51.4% reduction in his position. The sales occurred at the current market price of $48.57, at the 52-week high, following a 90-day gain of +25.0% in the stock. His cross-ticker track record shows a 90d well-timed rate of 0.00%, and his prior 5 trades at RPRX showed modest 30-day gains (+3.1% to +3.9%) with only recent 30-day outcomes measurable; no 90-day outcomes are yet available for comparison at this ticker. The scale of the reduction and proximity to the 52-week high merit monitoring, though the pattern against his historical cross-ticker timing record offers limited predictive signal.

CFO Terrance P. Coyne sold 34,791 shares of RPRX at $45.53 on 2026-03-23 for $1,583,989.00

Coyne, EVP & CFO, executed two separate sales totaling 34,791 shares (34.8K shares) at $45.53, reducing his holdings by 44.2% from 78.7K to 43.9K shares. The sales occurred near the stock's 52-week high of $47.48 (current price $47.03), with the stock up 3.4% over 30 days and 19.8% over 90 days—a period of sustained positive performance. His cross-ticker track record shows 20 prior sells with a 90-day well-timed rate of 0.00%, indicating his historical sell decisions have not preceded price declines; conversely, the average 90-day return of +17.5% after his prior sells suggests the stock typically rises following his exits. At RPRX specifically, four recent sales on 2026-03-02 lack measurable outcomes, while an earlier sale on 2026-02-23 showed a 30-day return of +3.8%, continuing the pattern of positive returns after his sales at this ticker.

CFO Coyne sells 34,791 shares (43.2% reduction) for $1.6M at $46.78 avg, stock near 52-week high

Terrance P. Coyne, EVP & CFO of Royalty Pharma, executed 4 separate sales on 2026-03-02 totaling 34,791 shares for $1,627,533.79, reducing his position from 80,552 to 45,761 shares. The blended average price of $46.78 aligns closely with the current price of $47.43 and comes within 0.1% of the 52-week high of $47.48, suggesting the sales occurred near the stock's peak valuation. This follows a pattern of recent same-ticker selling activity (5 prior sales at RPRX in early February 2026), and occurs in a stock posting strong near-term momentum: 30-day return of +12.0% and 90-day return of +21.2%. The 43.2% reduction in Coyne's holdings represents a material decrease in personal exposure to the company, though his cross-ticker track record shows prior sells have not been well-timed (90d well-timed rate of 0.00%, with average 90d return post-sell of +17.2%), meaning historically his sales have preceded further gains rather than declines.

CFO Coyne sells 34.8K shares ($1.6M) at RPRX, reducing stake 42.2%; fifth consecutive sell in 3 weeks

Terrance P. Coyne, EVP & CFO, executed two separate sales on 2026-02-23 totaling 34,791 shares for $1,576,606.35 at $45.32, reducing his holdings from 82,427 shares to 47,636 shares (a -42.2% reduction). This sale is notably part of a pattern: the SAME-TICKER HISTORY shows five prior transactions at RPRX—three sells on 2026-02-03, two on both 2026-02-04 and 2026-02-02—all clustered within the preceding three weeks. The current stock price of $45.15 is -0.7% below the 52-week high of $45.47, and the stock has appreciated +11.6% over the past 30 days and +13.3% over 90 days, positioning this sale near recent highs. RPRX fundamentals remain solid with $609.3M quarterly revenue, $288.2M net income, +5.1% annual growth, and a P/E of 25.95. The frequency of CFO dispositions in rapid succession, combined with sustained near-peak pricing and strong recent momentum, merits tracking of whether this reflects scheduled liquidity or a change in the executive's forward view.

CFO Terrance Coyne sold 243,541 shares (91.4% of holdings) for $10.4M across 6 separate sales Feb 2–4 at $42.08–$43.29

Terrance P. Coyne, EVP & CFO of Royalty Pharma plc (RPRX), executed 6 separate sales totaling 243,541 shares for $10,360,814.09 between February 2–4, 2026, reducing his holdings from 266,426 shares to 22,885 shares — a reduction of 91.4%. The sales occurred at prices ranging from $42.08 to $43.29 (blended average $42.54), near the stock's current price of $43.68 and at the 52-week high. At the same-ticker level, Coyne's prior 5 trades at RPRX were all sells, with measurable outcomes showing near-term appreciation: the December 2025 and January 2 sales posted +4.8% and +8.5% 30-day returns respectively, indicating the stock rallied after those sales. The magnitude of this disposal — eliminating 91.4% of holdings in a single filing across a 3-day window — represents a material shift in executive equity stake and warrants attention to the Company's strategic outlook and financial position, particularly given the revenue contraction (-3.9% annual growth) and P/E of 22.17.

Coyne (EVP & CFO) sold 69,582 shares for $2.7M at $39.35; holdings fall 65.9% to 36.0K shares.

Terrance P. Coyne, EVP & CFO of Royalty Pharma plc, executed 2 separate sales totaling 69,582 shares for $2,737,940.37 at $39.35 on 2026-01-20. This represented a significant reduction of holdings from 105,592 shares to 36,010 shares post-transaction, a net change of -65.9% of pre-transaction holdings. The timing occurred near recent price highs (current $40.40 is -2.4% from the 52-week high of $41.39), and the stock has risen +2.9% over 30 days and +8.4% over 90 days. Coyne's cross-ticker track record shows 16 prior sells with a well-timed rate of 100.00% at the 90-day mark, though at this specific ticker (RPRX) prior sales timing outcomes remain largely unmeasured or mixed. The magnitude of this reduction and the CFO's position warrant monitoring of the underlying business context and any subsequent disclosures.

Royalty Pharma CFO Coyne Terrance P. sold 69,582 shares for $2,673,041.24 on 2026-01-02

Coyne Terrance P., EVP & CFO of Royalty Pharma plc, executed 2 separate sales totaling 69,582 shares (69.6K shares) for $2,673,041.24 ($2.7M) at $38.42 per share on 2026-01-02, reducing his holdings by 63.6% from 109,342 shares to 39,760 shares. The transactions occurred near the stock's 52-week high of $40.78 (current price $40.65, -0.3% from that peak), and his prior sales at this ticker have not yet generated measurable 90-day outcomes; within his cross-ticker track record, his 14 prior sells averaged -1.2% over 30 days and -11.5% over 90 days with a 100.00% well-timed rate. The company's revenue declined 3.9% year-over-year while maintaining a 20.63 P/E ratio and $15.8B market cap, providing context for this significant insider reduction of equity exposure.

CFO Coyne sells 69,582 shares at $38.36 for $2,669,172.48; -61.5% reduction in RPRX holdings.

Terrance P. Coyne, EVP & CFO, executed 2 separate sales totaling 69,582 shares at $38.36 on 2025-12-15, reducing his stake from 113,092 shares to 43,510 shares—a -61.5% reduction in pre-transaction holdings. The sales occurred at $38.36, near the current price of $38.31 and within the 52-week range of $24.28–$40.78. Coyne's cross-ticker track record shows 12 prior open-market sells with a 90-day well-timed rate of 100.00% and average 90-day return of -11.5%, indicating his past sales have generally preceded stock declines; however, at RPRX specifically, his 5 most recent sales (all completed 2025-11-24 and 2025-12-01) remain unmeasurable at 90-day horizons. The substantial reduction in his ownership position warrants observation of near-term price action and any disclosures regarding company fundamentals or forward guidance.